secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001493152-25-018091
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics raises $2.5M in registered direct offering and warrant issuance
--------------------------------------------------------------------------------

- Gross proceeds of $2.5M from sale of 3,125,000 ADSs at $0.80 per ADS; Ladenburg Thalmann as placement agent.
- Concurrent private placement: Series E (5-year) and Series F (30-month) warrants to purchase up to 3.125M ADSs each at $0.98 exercise price; exercisable upon shareholder approval.
- Proceeds to fund working capital, general corporate purposes, and R&D; includes generating data on ADC payload AKTX-101 for SITC meeting.
- Offering expected to close on or about October 16, 2025, subject to customary closing conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225018091/0001493152-25-018091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225018091/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer